Lexaria Bioscience enters new exec agreement with President/CSO Docherty; base salary, 50% bonus, 15-mo severance

Lexaria Bioscience Corp.

New agreement effective Jan 1, 2025, replaces prior 2022 pact; Docherty remains President and Chief Scientific Officer.
Base salary subject to 5% annual increases on Jan 1, 2026 and Jan 1, 2027; performance bonuses up to 50% of base.
Change of control: up to 24 months base salary plus 2% of affiliate sale value, payable within 90 days.
Severance without cause or for good reason: 15 months base salary, increasing by 1 month per additional year to max 24 months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.